Today: The 609 Shares of Laboratory Corp. of America Holdings (LH) are sold by Bbva Compass Bancshares Inc.

The 609 Shares of Laboratory Corp. of America Holdings (LH) are sold by Bbva Compass Bancshares Inc.

Bbva Compass Bancshares Inc. reduced its stake in shares of Laboratory Corp. of America Holdings (NYSE:LH) by 5.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,586 shares of the company’s stock after selling 609 shares during the period. Bbva Compass Bancshares Inc.’s holdings in Laboratory Corp. of America Holdings were worth $1,510,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in LH. Nordea Investment Management AB increased its position in Laboratory Corp. of America Holdings by 0.7% in the second quarter. Nordea Investment Management AB now owns 2,906,174 shares of the company’s stock valued at $378,587,000 after buying an additional 19,479 shares during the last quarter. Geode Capital Management LLC increased its position in Laboratory Corp. of America Holdings by 1.5% in the first quarter. Geode Capital Management LLC now owns 846,284 shares of the company’s stock valued at $98,931,000 after buying an additional 12,480 shares during the last quarter. UBS Group AG increased its position in Laboratory Corp. of America Holdings by 92.7% in the first quarter. UBS Group AG now owns 749,888 shares of the company’s stock valued at $87,834,000 after buying an additional 360,652 shares during the last quarter. Bridger Management LLC purchased a new position in Laboratory Corp. of America Holdings during the first quarter valued at approximately $77,658,000. Finally, Lazard Asset Management LLC purchased a new position in Laboratory Corp. of America Holdings during the first quarter valued at approximately $75,588,000. Hedge funds and other institutional investors own 91.85% of the company’s stock.

Shares of Laboratory Corp. of America Holdings (NYSE:LH) traded up 0.17% on Monday, hitting $136.02. The stock had a trading volume of 123,612 shares. Laboratory Corp. of America Holdings has a 1-year low of $97.79 and a 1-year high of $141.32. The company has a market capitalization of $13.91 billion, a PE ratio of 22.58 and a beta of 0.86. The firm has a 50-day moving average of $136.70 and a 200 day moving average of $131.32.

Laboratory Corp. of America Holdings (NYSE:LH) last posted its quarterly earnings results on Wednesday, July 27th. The company reported $2.31 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. The company had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.33 billion. Laboratory Corp. of America Holdings had a net margin of 6.64% and a return on equity of 17.01%. Laboratory Corp. of America Holdings’s revenue was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.09 EPS. On average, equities analysts anticipate that Laboratory Corp. of America Holdings will post $8.81 earnings per share for the current fiscal year.

Several equities analysts have recently commented on the company. Evercore ISI upped their target price on Laboratory Corp. of America Holdings from $147.00 to $155.00 and gave the company a “buy” rating in a research report on Wednesday, July 27th. Canaccord Genuity set a $155.00 target price on Laboratory Corp. of America Holdings and gave the company a “buy” rating in a research report on Thursday, July 28th. Zacks Investment Research downgraded Laboratory Corp. of America Holdings from a “buy” rating to a “hold” rating in a research report on Friday, August 19th. KeyCorp upped their target price on Laboratory Corp. of America Holdings from $143.00 to $150.00 and gave the company an “overweight” rating in a research report on Tuesday, August 16th. Finally, Mizuho upped their target price on Laboratory Corp. of America Holdings from $132.00 to $145.00 and gave the company a “neutral” rating in a research report on Thursday, September 15th. Eight analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Laboratory Corp. of America Holdings presently has an average rating of “Buy” and a consensus target price of $141.57.

In other Laboratory Corp. of America Holdings news, insider Lisa J. Uthgenannt sold 1,177 shares of the business’s stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $140.00, for a total transaction of $164,780.00. Following the sale, the insider now owns 3,660 shares of the company’s stock, valued at approximately $512,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert E. Mittelstaedt, Jr. sold 992 shares of the business’s stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $140.15, for a total transaction of $139,028.80. Following the sale, the director now directly owns 12,340 shares in the company, valued at approximately $1,729,451. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

Laboratory Corp. of America Holdings Company Profile

Laboratory Corporation of America Holdings is a healthcare diagnostics company. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Related posts

Leave a Comment